Related Pages for DRREDDY

Option Chain
Max Pain
Put Call Ratio
Option Analytics
Call OI vs Put OI
Call OI Chg vs Put OI Chg
Call Vol vs Put Vol
Vega Divergence
Buildup & Unwinding
Strike Flow
Future Chain
Future Intraday Analysis
Technical
Financials
Chart
About

Search Symbol
DRREDDY
Dr. Reddy S Laboratories

1270 -9.90 (-0.77%)

L: 1264.5 H: 1288.3
Option
- Option
- Option Chain
- Max Pain
- Put Call Ratio
- Option Analytics
Option Analysis
- Option Analysis
- Call OI vs Put OI
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Vega Divergence
- Buildup & Unwinding
- Strike Flow
Futures
- Futures
- Future Chain
- Future Intraday Analysis
Company
- Company
- Technical
- Corporate Events & News
- Financials
- Chart
- About

🎨 Holi Special Offer! Get +30 Free Days on Yearly or +10 Free Days on Quarterly — Ends 8th Mar Midnight. View Plans → 🎨 Holi Offer — Ends 8th Mar - View Plans →

NiftyInvest

Market
Max Pain
Put Call Ratio
Option

Option Chain

Straddle Option Chain

Max Pain

Max Pain Table

Put Call Ratio

Put Call Ratio Table

Option Analytics

Option Screener

Call OI vs Put OI

StrikeFlow: Call vs Put Positioning

Call OI Change vs Put OI Change

Call Vol vs Put Vol

Buildup & Unwinding

Vega Divergence

Strategy Builder

Strategy Simulator

Multi Strike OI New

Price vs OI New

Time Series New

Volatility Skew New

Near ATM OI New
Future
Company
Live News
Pricing
My View
Login
Sign-up

[--[65.84.65.76]--]

DRREDDY

Dr. Reddy S Laboratories

1270 -9.90 (-0.77%)

L: 1264.5 H: 1288.3

0 results

No results found.

DRREDDY 1270

-9.9 (-0.77%)

Search symbol e.g. NIFTY, RELIANCE, CRUDEOIL

Corporate Actions
Related News

Loading corporate actions

Related News - DRREDDY

Dr. Reddy: Labs Plans To Introduce Oral And Injectable Semaglutide In All Markets In The Future.

12 May 2026 06:28 PM

Dr. Reddy: Labs Plans To Introduce Oral And Injectable Semaglutide In All Markets In The Future.

Dr Reddy: Labs Plans To Launch Semaglutide In Canada And India Soon This Month.

12 May 2026 05:59 PM

Dr Reddy: Labs Plans To Launch Semaglutide In Canada And India Soon This Month.

DR REDDY'S LABS: Q4 CONS NET PROFIT 2.21B RUPEES VS 15.94B (YOY) || Q4 REVENUE 75.46B RUPEES VS 85.3B (YOY)

12 May 2026 04:47 PM

DR REDDY'S LABS: Q4 CONS NET PROFIT 2.21B RUPEES VS 15.94B (YOY) || Q4 REVENUE 75.46B RUPEES VS 85.3B (YOY)

DR REDDY'S LABS: Q4 EBITDA 3.8B RUPEES VS 19.98B (YOY) || Q4 EBITDA MARGIN 5.07% VS 23.43% (YOY)

12 May 2026 04:48 PM

DR REDDY'S LABS: Q4 EBITDA 3.8B RUPEES VS 19.98B (YOY) || Q4 EBITDA MARGIN 5.07% VS 23.43% (YOY)

DR REDDY'S LABS: BOARD RECOMMENDS FINAL DIVIDEND OF ₹8 PER SHARE

12 May 2026 04:48 PM

DR REDDY'S LABS: BOARD RECOMMENDS FINAL DIVIDEND OF ₹8 PER SHARE

Dr Reddy’s Labs: Citi maintains 'Sell' on DrReddy with Price Target of Rs 990

08 Jan 2026 07:48 AM

Dr Reddy’s Labs: Citi maintains 'Sell' on DrReddy with Price Target of Rs 990

Empowering traders with comprehensive investment insights and advanced market analysis tools. Real-time data, intelligent analytics, and cutting-edge trading intelligence for the Indian stock markets.